Assessing Glutamine Metabolism in MGUS and Myeloma

Overview

About this study

The utilization of glutamine by the bone marrow plasma cells in MGUS and MM will be compared between each other after infusion of 13-carbon labelled glutamine.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

IMWG criteria for the diagnosis of either MGUS or MM5.
Presence of measurable disease defined by an M-spike of >1 g/dL and/or involved serum free immunoglobulin light chain >10 mg/dL.

For MGUS cohort only:

At least 5 to <10% cPCs in the prior BM aspirate.
Not received any plasma cell directed therapy.

For MM cohort

At least >10% cPCs in recent BM aspirate.
Newly diagnosed MM without receiving any plasma cell directed therapy OR Relapsed MM without having received salvage chemotherapy.

Exclusion Criteria:

For both MGUS and MM cohorts:

Unable to provide consent.
ECOG PS >1.
Hemoglobin < 8g/dL.
GFR <50 ml/min.
Women who are pregnant.
Abnormal liver function tests.
Abnormal bleeding history or coagulation profile (INR >1.5).
Prior history of adverse events with conscious sedation.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Wilson Gonsalves, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Wilson Gonsalves, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials